Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Maintains Underweight on Bed Bath & Beyond, Lowers Price Target to $13

Keybanc maintains Bed Bath & Beyond (NASDAQ:BBBY) with a Underweight and lowers the price target from $14 to $13.

byBenzinga Newsdesk

October 14, 2021

1 minute read

Keybanc maintains Bed Bath & Beyond (NASDAQ:BBBY) with a Underweight and lowers the price target from $14 to $13.

Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $395

By Benzinga Newsdesk

Today, 9:24 AM

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $461 to $395.

MRNA

Jushi Is Now Vertically Integrated In Nevada Via Acquisition Of The Apothecarium

By Nina Zdinjak

Today, 9:24 AM

Jushi Holdings Inc. (CSE: JUSH) (OTCQX: JUSHF) confirmed Wednesday it has signed an agreement to buy 100% equity interest of an entity operating a recreational and medical dispensary under the name The Apothecarium in Las Vegas, Nevada.

CSE:JUSH

Genius Sports Partners With Australian Professional Leagues

By Shivani Kumaresan

Today, 9:24 AM

Genius Sports Ltd (NYSE:GENI) has partnered with the Australian Professional Leagues (APL) to be the exclusive Official Data Partner…

GENI

Marathon Oil, Phillips 66 And Other Energy Stocks From Benzinga’s Most Accurate Analysts

By Lisa Levin

Today, 9:24 AM

US stocks closed sharply higher, with the energy stocks recording sharp gains on Monday. Energy sector surged around 2.5% in the session.

EOG

Keybanc Maintains Underweight on Bed Bath & Beyond, Lowers Price Target to $13

Related Posts

Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $395

Jushi Is Now Vertically Integrated In Nevada Via Acquisition Of The Apothecarium

Genius Sports Partners With Australian Professional Leagues

Marathon Oil, Phillips 66 And Other Energy Stocks From Benzinga’s Most Accurate Analysts